TIMOTHY MICHAEL WRIGHT
CIK 1686178 · Chief R & D Officer · last filed 2020-02-10
TIMOTHY MICHAEL WRIGHT is a Chief R & D Officer who has filed 9 SEC Form 4 insider transactions across 2 companies since 2016. The most recent filing, for SDGR, was dated Feb 10, 2020. Across all open-market trades the lifetime net is +$250.0K, making them a net buyer over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
2
9
$250.0K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SDGR | Director | — | $14.45 | — | $0 | 1 | 2020-02-10 |
| Regulus Therapeutics Inc. (RGLS) Delisted | Chief R & D Officer | 62,893 | $8.16 | $513.2K | $250.0K | 8 | 2019-02-06 |
Recent Filings
9 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-02-10 | SDGR | Grant (A) | — | $0 | EDGAR |
| 2019-02-06 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | +40,000 | $38.0K | EDGAR |
| 2018-05-21 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-01-05 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-12-05 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-07-25 | Regulus Therapeutics Inc. (RGLS) Delisted | Buy (P) | +274,725 | $250.0K | EDGAR |
| 2017-05-08 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-02-23 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-10-05 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | — | $0 | EDGAR |